Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159193 | 0.87 | KMT2A (0.55) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7611722 | 0.82 | PDE10A (0.51) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28448602 | 0.79 | USP2 (0.77) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5159131 | 0.79 | POLB (0.49) | KMT2ACYP1A2CYP3A4USP2ALDH1A1 | |
| SCHEMBL5156390 | 0.71 | CXCR3 (0.46) | POLBKCNH2HRH3 | |
| SCHEMBL24098581 | 0.70 | MEN1 (0.54) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29110461 | 0.70 | HRH3 (0.63) | KMT2AMEN1ALDH1A1POLBKCNH2 | |
| SCHEMBL409520 | 0.70 | MEN1 (0.80) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7020221 | 0.70 | ALDH1A1 (0.63) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7511098 | 0.70 | PDE10A (0.67) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559160-B1 | These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, | CHEMOCENTRYX, INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1216232-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR MODULATING CXCR3 FUNCTION | Chemocentryx, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001016114-A2 | HETEROCYCLIC COMPOUNDS AND METHODS FOR MODULATING CXCR3 FUNCTION | CHEMOCENTRYX, INC. (US) | 2001-03-08 | — | — | WO | disclosed |